Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Open Label Dose Escalation Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of SC16LD6.5 as a Single Agent in Patients With Recurrent Small Cell Lung Cancer

NCT01901653 is registered in ClinicalTrials.gov with Stemcentrx as lead sponsor.

NCT NCT01901653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01901653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Open Label Dose Escalation Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of SC16LD6.5 as a Single Agent in Patients With Recurrent Small Cell Lung Cancer
Lead sponsor
Stemcentrx
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2013
Completion date
November 28, 2016
Enrollment
82 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent small cell lung cancer